Xiaolin Zhang

Xiaolin Zhang, listed as board member, appears in our data through filings on 迪哲医药 shares, published by SSE / SZSE (CSRC). In total, 8 filings cover trades dated from 5 February 2024 to 7 May 2025.

In open-market terms, that means 2 purchases worth €5.0M on one side and 6 sales worth €11.9M on the other. The net balance comes to €6.9M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2025 to date brings no purchases and 6 sales.

Most recently, on 7 May 2025, the filings show an open-market sale worth €3.2M in 迪哲医药. The latest purchase dates back some time: it was published 989 days ago, on 8 February 2024. Half of the filings or more reach the SSE / SZSE (CSRC) feed on the day of the trade. This delay matters because a trade only becomes useful information once it is public. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.